Business
Lifeline Biotechnologies Announces a Cyrcadia Milestone and 2016 Expectations
Lifeline Biotechnologies Announces a Cyrcadia Milestone and 2016 Expectations.
About this update from Lifeline Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n Lifeline Biotechnologies Announces a Cyrcadia Milestone and 2016 Expectations\n \n \nLifeline Biotechnologies Announces a Cyrcadia Milestone and 2016 Expectations\n \n RENO, NV--(Marketwired - Apr 1, 2016) - Lifeline Biotechnologies, Inc. (\"The Company\") (OTC PINK: LLBO), in conjunction with its affiliate Cyrcadia, Inc. (\" Cyrcadia\"), is pleased to announce the achievement of a major milestone in Cyrcadia's regulatory and business development path. Cyrcadia Health announced the extension of its clinical trial for early breast cancer detection to The Stefanie Spielman Comprehensive Breast Center at The Ohio State University, in Columbus, Ohio. The trial, which began in 2015 at El Camino Hospital, in Mountain View, California, will continue at both locations to reach enrollment of 173 patients focused on breast cancer health screening.\n \"We are targeting both the 70 percent of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, as well as mass screening of patients with dense breasts,\" said Rob Royea, President of Cyrcadia. \"Patients with dense breast tissue have a higher propensity for cancer. Furthermore, mammography is challenged by detecting cancer in dense breast tissue as it can mask cancer cells and lesions.\"\n \"We have had a great deal of interest in this technology that may change the need for a breast biopsy,\" said Dr. Shyamali Singhal, founder of the El Camino Hospital Cancer Center. \"The trial at El Camino Hospital opened with strong interest from the patient population and the early results are indeed promising. We look forward to further involvement with the Cyrcadia study here at El Camino Hospital.\" \n \"The expansion of the study to The Ohio State University is truly exciting, as The Ohio State University was the point of origin for the original 500 patient study conducted with our previous FDA cleared device,\" said Royea. \"Dr. William Farrar, Professor, Division of Surgical Oncology, Department of Surgery, and Medical Director of the Stefanie Spielman Comprehensive Breast Center was one of our original researchers. His confidence to include the Cyrcadia study at one of the nation's highest rated cancer hospitals is a significant complement to our early clinical trial progress. As we evaluate and potentially add new sites to the ...